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Treatment options for severe pneumonia: Focus on Pseudomonas Pneumonia
Benjamin Margono*
Abstract
Pneumonia due to Pseudomonas aeruginosa occurs in several distinct syndromes: 
1/ Community Acquired Pneumonia (CAP) usually in patients with chronic 
lung disease e.g.: COPD / Cystic Fibrosis / bronchiectasis. Rather uncommon : 
0.9%-1.9% of patients with CAP requiring hospitalization.  2/ Hospital Acquired 
Pneumonia (HAP), usually occurring in the ICU after day 4 or VAP. Much more 
common : 18%. 3/ bacteremic ,  usually in the neutropenic host e.g. hematologic 
malignancy, HIV ( Pre HAART : 8-25%; HAART era: 5-6.7%)
P.aeruginosa. is a gram negative rod that is ubiquitous in nature and is an 
opportunistic pathogen in humans. It is a particularly virulent pathogen that 
produces many virulent factors, including exotoxins, enzymes and biofilms that 
protects it from host antibodies and phagocytes.
Pseudomonas pneumonia carries a notably higher mortality rate than other 
pneumonia pathogens. Therapy has always been challenging magnified in recent 
years by the emergence of MDR (multi drug resistant) and PDR ( Pan drug resistant ) 
pathogen, compounded further by the diagnostic problem of differentiating between 
colonization and infection, as blood cultures are rarely positive and gram stains 
have not proven useful.
Anti Pseudomonal antibiotics : Aminoglycosides; .β Lactam congeners; 
Monobactam; Extended spectrum penicillins e,g, piperacillin-tazobactam,  
Carbapenems; anti pseudomonal fluoroquinoles; Colistin. Combination antibiotic 
therapy may potentially broaden the antimicrobial spectrum, provide synergistic 
interaction, decrease emergence of antimicrobial resistance and minimize 
superinfection.
Incombination antibiotic therapy the greatest synergy is obtained by combining an 
aminoglycoside(A) + antipseudomonal penicillin (~90%), followed in decreasing 
order  A + cephalosporin (~ 80%) then A + carbapenem (~50%), while the interaction 
of a fluoroquinolone + A or βlactam  is usually indifferent or autonomous. 
Given the nephrotoxicity of aminoglycosides the following algorithm is proposed : 
Combination of an anti-pseudomonal penicillin + an aminoglycoside for 3-5 days, 
then replace the aminoglycoside with an anti-pseudomonal fluoroquinolone for a 
total of 8-15 days.
Key Word : Pseudomonal Pneumonia is treatable and potentially curable
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INTRODUCTION:
To my unpleasant surprise SEVERE 
PNEUMONIA is not well defined in 
the literature, so for this paper it will be 
defined as pneumonia with a CPIS (clinical 
pulmonologic infection score) of ≥ 6 or 
CURB-65 of ≥ 3.(table 1-4)
Pseudomonas aeruginosa is a gram 
negative rod, ubiquitous in nature and 
opportunistic in humans. It is a particularly 
virulent pathogen that produces many virulent 
factors, including exotoxins and enzymes 
                              Table 1   
Table 2
        Table 3   
Table 4
and also biofilm that protects it from 
environmental elements, host antibodies and 
phagocytes. Among the anatomic sites of 
P.aeruginosa infection, the lung is associated 
with the highest mortality rate
PSEUDOMONAS PNEUMONIA:
Several distinct syndromes of 
P.aeruginosa respiratory tract infection exists:
1. Community acquired pneumonia 
(CAP):
•	 P.aeruginosa as the etiologic 
pathogen in CAP is quit rare : 
0.9-1.9% of patient with CAP 
requiring hospitalization, but 
crude mortality is high : 61.1%
•	 Risk factors for CAP caused 
by P.aeruginosa are:
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i. Chronic ling disease, 
especially COPD
ii. C o l o n i z a t i o n 
is an important 
a n t e c e d e n t a r y 
event , previous 
h o s p i t a l i z a t i o n 
(HCAP), intubation, 
enteral tube feeding.
iii. S m o k i n g , H I V 
infection
iv. Structural lung disease 
e.g. bronchiectasis
2. Hospital acquired pneumonia (HAP)
•	 In the US there is a gradual 
increase in the incidence of 
Pseudomonal HAP from 9.6% 
in 1975 to 18.1% in 2003
•	 P.aeruginosa is the most 
frequently isolated gram 
negative aerobic bacteria from 
the respiratory  tract (31.6%) 
•	 In Ventilator associated 
p n e u m o n i a ( V A P ) : 
P.aeruginosa was the most 
frequent  pathogen (9.3%) 
in patients with VAP, where 
pneumonia occurred after 
> 4 days after mechanical 
ventilation
3. P.aeruginosa bacteremia in the 
immunocompromised host.
P.aeruginosa in HIV patients:
•	 T r i m e t h o p r i m 
s u l f a m e t h o x a z o l e 
prophylaxis for pneumocystic 
pneumonia is associated 
significant protection 
against Toxoplasmosis, 
Salmonella, Haemophilus and 
Staphyloccus aureus, but NOT 
against S.pneumonia, non 
pneumococcal streptococcus 
and P.aeruginosa.
•	 In the HAART era the most 
common cause of HAP in HIV 
is P.aeruginosa, with a crude 
mortality of 23%. The median 
CD4 count at presentation 
ranged from 27 t0 42 cell/µL.
•	 But for CAP in the HAART era 
the most common cause is still 
S.pneumonia(30%-35.7%)
DIAGNOSIS
The most consistent finding radiologic 
findings was bilateral distribution of infiltrates, 
present in 48 - 91 % of cases.
Diagnosis of P.aeruginosa pneumonia 
is challenging because of relative ease 
of colonization of the upper and lower 
respiratory tract, giving rise to a colonization 
v/s infection problem. P. aeruginosa is a 
colonizer and pulmonary infiltrates does not 
necessarily represent infection
Because P.aeruginosa bacteremia is 
very rare in HAP, definitive confirmation 
of the etiologic role of P.aeruginosa is 
difficult. Prior antibiotic use is a risk factor 
for P.aeruginosa colonization. P.aeruginosa is 
the dominant species colonizing endotracheal 
aspirates. P.aeruginosa enhances mucous 
secretion, disrupts ciliary activity and causes 
airway epithelial injury, thereby impairing 
pulmonary clearance
Invasive procedures : protected brush 
bronchoscopy + quantitative cultures :
Colonization : bacteria counts < 10^3 cfu 
/ mL
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Infection :  bacteria counts > 10^3 
cfu / mL could be the 
procedure of choice
Anti pseudomonal antibiotic therapy 
based on respiratory tract culture may 
therefore lead to overtreatment. Quantitative 
cultures have proven to be effective in 
selecting patients who would benefit from 
antimicrobial therapy
Limiting antibiotics in the ICU with 
pulmonary infiltrates with CPIS ≤ 6, did NOT 
lead to higher mortality.
P.aeruginosa carries a notably higher 
mortality rate than other pneumonia pathogens. 
Therapy has always been challenging, because 
of its multiple mechanism 0f resistance
Mechanism of antibiotic resistance are 
summarized in table 5
 
ESBL = Extended-spectrum β-lactamases
Antibiotics that exhibit activity ≥ 70% 
against P.aeruginosa may be regarded as drug 
of choice (Table 6)
Table 6 : DRUG of CHOICE
Based on pharmacokinetics and 
pharmacodynamics ( PK/PD) in time-
dependent antibiotics eg. β-lactams, using 
continuous infusion or slowing the infusion 
from 1 to 4 hrs will increase the the time above 
MIC and result in higher bacterial kill. While the 
anti-pseudomonal quinolones : Ciprofloxacin 
and Levofloxacin, as concentration dependent 
antibiotics the AUC / MIC ratio defines the 
bacteria kill. Ciprofloxacin has a lower MIC ( 
0.5μg/ml) than Levoflocaxin (MIC 1.0μg/ml), 
but this advantage is offset by cipro’s lower 
serum and tissue concentration as compared 
to levo, resulting in similar potency against 
P.aeruginosa.
Of the carbapenems, doripenem is the 
most active against P.aeruginosa.
ANTIBIOTIC THERAPY
Mortality was 3.6 – 40.2 % in patients 
with appropriate empirical antibiotic therapy 
and increased to 17.6-81.6% in inappropriate 
empirical antibiotic therapy.
Combination antibiotic therapy 
can broaden the antimicrobial spectrum, 
synergistic interaction, decrease emergence 
of antimicrobial resistance and minimize 
superinfection. However demonstrated 
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improvement in outcome for combination therapy has been elusive.
The greatest likelihood of synergy is : 
AGENT + AGENT SYNERGY
AMINOGLYCOSIDE ANTI-PSEUDOMONAL PENICILLIN ~90%
AMINOGLYCOSIDE CEPHALOSPORIN ~80%
AMINOGLYCOSIDE CARBAPENEM ~50%
FLUORO-QUINOLONE AMINOGLYCOSIDE Additive/indifferent
FLUORO-QUINOLONE β-LACTAM Additive/indifferent
Mono-therapy of Fluoro-quinolone is 
NOT recommended, given the high likelihood 
of bacterial resistance (38%) and failure to 
achieve bacterial eradication (67%) 
Likewise, using an aminoglycoside 
carries the risk nephrotoxicity. It is proposed 
that to minimize nephrotoxicity the use of an 
aminoglycoside should be limited to≤ 5 days, 
then replace by a fluoro-quinolone.
RECOMMENDATION:
Based on PK/PD and synergy empirical 
antibiotic therapy in pseudomonas pneumonia 
is recommended to be a combination regiment 
of :
Anti – pseudomonal penicillin PLUS 
Aminoglycoside ≤ 5 days , then 
replace by an antipseudomonal fluoro-
quinolone (8-14 days)
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